Based on analyses from over 1,000 patients at two medical centers, a new study from Mass General Brigham suggests that the common medication gabapentin is associated with improved survival rates in individuals diagnosed with glioblastoma (GBM), the most aggressive type of brain cancer. The research indicates that gabapentin use was linked to an average of 4 to 6 months longer survival and may work by reducing levels of the protein TSP-1, which is known to promote tumor growth. While these retrospective findings are considered promising, further randomized clinical trials are necessary to confirm gabapentin's therapeutic potential for GBM patients.

https://neurosciencenews.com/gabapentin-glioblastoma-cancer-28936/